GUARDD-US is a pragmatic clinical trial enrolling patients of African ancestry with hypertension. Participants receive apolipoprotein L1 (APOL1) genetic testing, and the trial aims to determine the effect of returning APOL1 genetic risk information to patients and their primary care providers on systolic blood pressure (SBP). Participating from REACHnet are University Medical Center New Orleans and Baylor Scott & White Health.